Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500 million (USD 72.4 million) in a Series B round led by Cornerstone Capital, LYFE Capital, and Sky World Capital. The funding will enhance its CRO service capacity, smart manufacturing, R&D, and global expansion.
Funding Details
The round included participation from Haitong Innovation Securities, GOVTOR, ALAN AMC, Yueshi Capital, Gaorong Capital, Oct. Capital, Shanghai West Investment, Befor Capital, and returning investors CanNova and CS Capital. Proceeds will drive growth in antibody discovery services and overseas market development.
Company Profile
Founded in 2012 and operating in China and the U.S., Biointron offers end-to-end antibody development solutions, from target protein engineering to stable cell line development. Its clients span drug developers, diagnostics firms, vaccine makers, and cell therapy companies.
Technology Platform
Biointron’s platform covers single B cell antibody screening, humanization, affinity maturation, nanobody development, and stable cell line generation. The firm aims to leverage Series B funds to scale operations and strengthen its position in the global life sciences supply chain.
Strategic Outlook
The funding positions Biointron to accelerate innovation in antibody therapeutics and expand overseas channels. With demand rising for recombinant protein reagents, the company plans to enhance R&D and manufacturing efficiency to meet industry needs.-Fineline Info & Tech
